Aldeyra Therapeutics, Inc. (ALDX) is awaiting a key FDA decision on March 16, 2026, for its drug candidate Reproxalap, proposed for the treatment of dry eye disease.
Reproxalap is a first-in-class small-molecule modulator of reactive aldehyde species (RASP), which are elevated in ocular inflammation. The drug is designed to reduce symptoms like ocular discomfort and redness in patients with dry eye disease- a condition affecting millions and often under-treated.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.